Gut microbiome-intestinal epithelium axis (GM-IEA)

The gut microbiome and host intestinal epithelium constitute a critical biological interface that regulates systemic health and immune homeostasis. The intestinal epithelium serves as a selective barrier, facilitated by tight junction proteins, while the diverse microbial community contributes to metabolic processes and protects against pathogen colonization by producing essential metabolites like short-chain fatty acids (SCFAs) (Vancamelbeke & Vermeire, 2017, PMC5430012). Dysregulation of this axis, often involving increased epithelial permeability (commonly referred to as 'leaky gut') and altered microbial diversity, is a hallmark of diseases such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and various metabolic disorders (Hiippala et al., 2018, doi:10.3389/fimmu.2018.01618). Therapeutic interventions targeting this axis aim to restore balance by either directly manipulating the microbiome through probiotics, prebiotics, and fecal transplants, or by strengthening the epithelial barrier using small molecules like larazotide to prevent the translocation of luminal antigens (Gopalakrishnan et al., 2012, doi:10.1155/2012/250719). Because this target represents a multi-component system rather than a single molecule, it is classified as a physiological system or interface. Understanding the crosstalk between the microbiota and host cells remains a focal point for developing precision medicine approaches for chronic inflammatory and autoimmune conditions (Thursby & Juge, 2017, PMC5433529).

Other names

Gut-microbiota-host interfaceIntestinal mucosal barrier systemGut microbiome-epithelial crosstalkIntestinal barrier-microbiome unit

Modulation of microbial composition and diversity, reinforcement of epithelial tight junction proteins (e.g., zonulin antagonism), inhibition of pro-inflammatory cytokine signaling, and restoration of the mucosal mucus layer.